Understanding how each drug works and what distinguishes semaglutide vs tirzepatide can help individuals and clinicians make informed choices about treatment options
Numerous GLP-1 receptor-targeting drugs have been investigated in clinical studies for various indications, including type 2 diabetes and obesity (accounts for 70% of the total studies), non-alcoholic steatohepatitis, Alzheimer's disease, and Parkinson's disease
Another important point involves the type of thyroid cancer being evaluated
As Highmark makes a final push to redirect members to the new My Highmark App, the availability of these resources on that platform can help to keep Virtual Health accessibility front of mind to members
[1] The MHRA, NICE and NHS provide comprehensive guidance on the safe prescribing and monitoring of GLP-1 agonists, emphasising the importance of patient education regarding expected side effects and warning signs that warrant medical attention
Obesity Medicine
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
